Department of Pediatrics, Washington University School of Medicine, St. Louis, United States; Department of Biology, Washington University in St. Louis, St. Louis, United States
Ishaan T Shah
Department of Pediatrics, Washington University School of Medicine, St. Louis, United States
Jayda Hatten
Department of Pediatrics, Washington University School of Medicine, St. Louis, United States
Yasaman Barekatain
Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, United States
Department of Pediatrics, Washington University School of Medicine, St. Louis, United States; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Children’s Hospital of Philadelphia, Philadelphia, United States; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, United States
Carboxy ester prodrugs are widely employed to increase oral absorption and potency of phosphonate antibiotics. Prodrugging can mask problematic chemical features that prevent cellular uptake and may enable tissue-specific compound delivery. However, many carboxy ester promoieties are rapidly hydrolyzed by serum esterases, limiting their therapeutic potential. While carboxy ester-based prodrug targeting is feasible, it has seen limited use in microbes as microbial esterase-specific promoieties have not been described. Here we identify the bacterial esterases, GloB and FrmB, that activate carboxy ester prodrugs in Staphylococcus aureus. Additionally, we determine the substrate specificities for FrmB and GloB and demonstrate the structural basis of these preferences. Finally, we establish the carboxy ester substrate specificities of human and mouse sera, ultimately identifying several promoieties likely to be serum esterase-resistant and microbially labile. These studies will enable structure-guided design of antistaphylococcal promoieties and expand the range of molecules to target staphylococcal pathogens.